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Retention in care during the first 3 years of ART for women in Malawi's Option B+ programme 
 
Abstract 
Background: Studies of Malawi’s Option B+ programme for HIV-positive pregnant and breastfeeding women have 
reported high loss to follow-up during pregnancy and at the start of antiretroviral therapy (ART), but few data exist 
about retention during breastfeeding and after weaning. We examined loss to follow-up and retention in care in 
patients in the Option B+ programme during their first 3 years on ART. 
Methods: We analysed two data sources: aggregated facility-level data about patients in Option B+ who started ART 
between Oct 1, 2011, and June 30, 2012, at 546 health facilities; and patient-level data from 20 large facilities with 
electronic medical record system for HIV-positive women who started ART between Sept 1, 2011, and Dec 31, 2013, 
under Option B+ or because they had WHO clinical stages 3 or 4 disease or had CD4 counts of less than 350 cells per 
µL. We used facility-level data to calculate representative estimates of retention and loss to follow-up. We used 
patient- level data to study temporal trends in retention, timing of loss to follow-up, and predictors of no follow-up 
and loss to follow-up. We defined patients who were more than 60 days late for their first follow-up visit as having no 
follow-up and patients who were more than 60 days late for a subsequent visit as being lost to follow-up. We 
calculated proportions and cumulative probabilities of patients who had died, stopped ART, had no follow-up, were 
lost to follow-up, or were retained alive on ART for 36 months. We calculated odds ratios and hazard ratios to 
examine predictors of no follow-up and loss to follow-up. 
Findings: Analysis of facility-level data about patients in Option B+ who had not transferred to a different facility 
showed retention in care to be 76·8% (20 475 of 26 658 patients) after 12 months, 70·8% (18 306 of 25 849 patients) 
after 24 months, and 69·7% (17 787 of 25 535 patients) after 36 months. Patient-level data included 29 145 patients. 
14 630 (50·2%) began treatment under Option B+. Patients in Option B+ had a higher risk of having no follow-up and, 
for the first 2 years of ART, higher risk of loss to follow-up than did patients who started ART because they had CD4 
counts less than 350 cells per µL or WHO clinical stage 3 or 4 disease. Risk of loss to follow-up during the third year 
was low and similar for patients retained for 2 years. Retention rates did not change as the Option B+ programme 
matured. 
Interpretation: Our data suggest that pregnant and breastfeeding women who start ART immediately after they are 
diagnosed with HIV can be retained on ART through the Option B+ programme, even after many have stopped 
breastfeeding. Interventions might be needed to improve retention in the first year on ART in Option B+. 
Funding: Bill & Melinda Gates Foundation, Partnerships for Enhanced Engagement in Research Health, and National 
Institute of Allergy and Infectious Diseases. 
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Research in context 
Evidence before the study 
We searched PubMed from Sep 1, 2011 to Aug, 25, 2015 with the following query without any language restrictions: 
retention[tiab] OR attrition[tiab] OR adherence[tiab] OR mortality[tiab] OR loss to follow-up[tiab] OR lost to follow-
up[tiab] OR ART outcomes [tiab] OR evaluation [tiab]) AND (Option B+[tiab]. We aimed to find observational studies 
that describe retention in care among women who started ART under Option B+ indications. We also used the term 
“Option B+ to search IAS conference and Conference on Retroviruses and Opportunistic Infections abstracts from 
2015. We identified 16 eligible studies from low- and lower middle-income countries. Most described short-term 
outcomes and reported retention at 3, 6 and 12 months after ART initiation. A study from Haiti reported longer-term 
retention (24 months). Estimates varied widely between studies and countries. Two studies from Mozambique and 
two studies from Haiti reported very high early loss to follow-up and poor retention. In Mozambique, retention was 
50% after the first visit, and 33% after 12 months. In Haiti, retention was around 70% at 6 months, 50% at 12 months, 
and 30% at 24 months. One study in Uganda reported six-month retention of 88%, and a study in Cameroon found 
that six-month retention improved from 85% to 91%. Eleven studies in Malawi described retention among Option B+ 
patients. Six of these reported 6-month retention rates; results ranged from 72%-92%. Seven studies reported 
retention at 12 months; estimates ranged between 50% and 94%. A country-wide analysis of facility-level data showed 
that 77% of the women who started ART on Option B+ were still in care a year later.  
Added value of this study 
Our study is the first patient-level data analysis to describe retention in care among Option B+ patients throughout the 
course of breastfeeding and after its cessation. Over 70% of women who started ART on Option B+ were still in care 
three years later. For the first two years of ART, Option B+ women were more likely to be lost to follow-up than 
women who were not pregnant and who began ART for their own health. By year three, their risk of loss to follow-up 
was similar. Retention in care did not change as the Option B+ programme matured. 
Implication of all the available evidence 
Randomised controlled trials (eg, START and TEMPRANO) have provided evidence of the benefits immediate initiation 
of ART. Although long-term studies are needed to provide definative answers, our data suggest that pregnant and 
breastfeeding women who start ART immediately after they are diagnosed with HIV can be retained on ART. 
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Introduction 
In 2011, the Malawian Ministry of Health implemented the Option B+ programme for HIV-positive pregnant and 
breastfeeding women, which increases coverage of prevention of mother-to-child transmission (PMTCT) services, 
improves maternal health, and reduces transmission to serodiscordant sexual partners. Option B+ provides lifelong 
antiretroviral therapy (ART) for all HIV-infected pregnant and breastfeeding women, irrespective of CD4 count or 
WHO clinical stage.
1–3 In Malawi, women in Option B+ receive a fixed dose combination of tenofovir, lamivudine, 
and efavirenz.
1,2 PMTCT services are integrated into antenatal care, maternity, and postnatal clinics, clinics for 
children younger than 5 years, and specialised HIV clinics.
2,4  HIV testing and PMTCT services are offered in primary, 
secondary, and tertiary care facilities.5 When the Option B+ programme was implemented on a national scale, the 
number of pregnant women who initiated ART quickly rose
5
 and PMTCT coverage increased substantially, from 49% in 
2011,
3 to 85% in 2014.
6 
Option B+ has greatly improved coverage of PMTCT services, but women must stay on ART for their whole lives if 
they7–10 and their communities11 are to receive the full individual and public health benefits of treatment. Qualitative 
evidence suggests that women are strongly motivated to protect their children from prenatal and postnatal HIV 
transmission by staying on ART while pregnant and breastfeeding. However, they might see less need for treatment 
after they stop breastfeeding. Many patients in Option B+ are asymptomatic when diagnosed with HIV, so they might 
be less motivated to stay on ART to protect their own health than to protect their children’s health.12,13 
Studies of Option B+ have shown high rates of loss to follow-up during the ﬁrst 6–12 months of ART,5,14 but data about 
long-term retention are very scarce: aggregated facility-level data from Malawi’s HIV programme reports6 show that 
retention in the Option B+ programme at 3 years is about 70%, but no analyses of patient-level data have been 
published. 
We used country-wide facility-level data to calculate representative estimates of retention and loss to follow-up and 
patient-level data from 20 large health-care facilities to study temporal trends in retention and exact timing and 
predictors of loss to follow-up. We followed up women from the start of ART for up to 3 years to describe retention 
during pregnancy and breastfeeding and after breastfeeding. 
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Methods 
Study design and participants 
We did cohort analysis of facility-level aggregated data from 546 health facilities in the national Option B+ programme 
and patient-level data from 20 large health facilities. The National Health Sciences Research Committee (number 962) 
and the Cantonal Ethics Committee of Bern (number IRB00003905 FW A00005976) granted ethical approval for the 
study. 
In our analysis of facility-level data, we included women registered between Oct 1, 2011, and June 30, 2012, who had 
Option B+ as their indication for starting ART. We chose the study period to ensure that all patients had started ART at 
least 3 years before the database closed on June 30, 2015. We restricted the analysis to health facilities with available 
data for 6, 12, 24, and 36 months to ensure that the ART outcomes were comparable over time. We excluded patients 
who transferred to another facility before their ART outcome was assessed. In a sensitivity analysis, we included data 
from all facilities, irrespective of the completeness of the data. 
To examine temporal trends in retention and exact timing and predictors of loss to follow-up, we analysed patient-
level data from women who started ART between Sept 1, 2011, and Dec 31, 2013, at 20 large health facilities in 
central and southern Malawi which used an electronic medical record system when the Option B+ programme was 
implemented (Figure S1, appendix). We included treatment-naive women who started with Option B+ as their 
indication for ART and women who started ART because they had WHO clinical stage 3 or 4 disease or CD4 counts less 
than 350 cells per μL. 
Procedures 
The medical records of patients taking ART at facilities with fewer than 2500 patients are noted on paper-based 
treatment cards and entered in paper-based clinical registers. Facility-level data are collected from all integrated ART 
and PMTCT facilities during quarterly supervision visits by representatives from the Ministry of Health. Key outcomes, 
including the number of patients who initiated ART, the number of patients who were lost to follow-up, died, 
transferred-out, stopped ART, or were retained on ART at 6, 12, 24, and 36 months, are extracted from treatment 
cards and aggregated at each facility.
2,6
 To collect patient-level data at large facilities (ie, those with >2500 patients), 
health-care workers use an electronic medical record system operated by the Baobab Health Trust (Lilongwe, Malawi). 
Barcode scanners and touchscreen displays are used to collect patient-level data at the point of care.15 Baseline and 
longitudinal measurements of clinical staging, ART history, laboratory results, clinic visits, pharmacy claims, and ART 
outcomes (loss to  follow-up, death, transfer out, stopped ART, or retained alive on ART) are recoded in the electronic 
medical record system. We extracted patient-level data from the electronic medical record system, and facility-level 
data from the central database of the HIV Department at the Ministry of Health of Malawi. 
We categorised patients according to their eligibility for ART and then compared outcomes between groups of 
patients. We classiﬁed patients as eligible for ART for their own health if they were not pregnant or breastfeeding and 
had reached WHO clinical stage 3 or 4 disease or had a CD4 count less than 350 cells per μL. We classiﬁed patients as 
eligible for Option B+ because of pregnancy if they began ART while pregnant, or as eligible for Option B+ because of 
breastfeeding if they were breastfeeding when they started ART, irrespective of their clinical or immunological stage. 
We based our deﬁnition of patients’ cumulative medication adherence on data from pharmacy claims recorded in the 
electronic medical record system and we decided that cumulative medication adherence would be the percentage of 
days pharmacy records showed that drugs were available to a patient (ie, days covered by the prescriptions patients 
had collected). 
Outcomes 
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We deﬁned patients who stopped taking ART and were known to be alive, as having stopped ART. Patients were 
deﬁned as dead if the health facility received a reliable report that they had died from any cause. Patients who had 
not died, transferred out, or stopped ART, and who were more than 60 days late for their ﬁrst follow-up visit were 
classiﬁed as having no follow-up. Patients who were more than 60 days late for a subsequent follow-up visit were 
counted as lost to follow-up.
2
 We judged loss to follow-up of less than 5% per year on ART to be low, 5–10% to be 
moderate, and more than 10% to be high. Patients who were not classiﬁed as having no follow-up or being lost to 
follow-up and who had not died, transferred out, or stopped ART were deemed to be retained alive on ART. In an 
analysis of temporal trends in retention, we adapted our standard deﬁnition of loss to follow-up. In the other 
analyses, retained patients included those who were classiﬁed as lost to follow-up, but who later returned to care. We 
could not use this deﬁnition to analyse temporal trends in retention because transient treatment interruptions 
diﬀerentially aﬀect patients enrolled in diﬀerent time periods. If ART is interrupted in a recently enrolled patient (ie, 
an individual who enrolled near the end of the study period), the patient has less time to return to care than do 
patients enrolled earlier, making it more likely that recently enrolled patients who temporarily interrupt care will be 
classiﬁed as lost.
16
 To avoid bias in our analyses of temporal trends of retention, we classed patients as lost to follow-
up if they were more than 150 days late for an appointment, and counted them as lost to follow-up, even if they later 
returned. We chose a longer time window because classiﬁcation of those patients absent from care for more than 150 
days after their last missed appointment (about 180 days after last visit) as lost to follow-up minimises 
misclassiﬁcation.17 
Statistical analysis 
We analysed facility-level data to calculate representative estimates for Option B+ programme retention. We used 
descriptive statistics and calculated the proportions of Option B+ patients who had died, stopped ART, were lost to 
follow-up, or who were retained in care at 6, 12, 24, and 36 months. 
We used survival analysis methods to analyse the patient-level data from 20 large health facilities. Patients were 
followed up from the beginning of ART for up to 36 months. We censored patients at the date at which an ART 
outcome was recorded or when they were no longer at risk of loss to follow-up (60 or 150 days before closing date, 
depending on the time window that deﬁned loss to follow-up). We viewed no follow-up, loss to follow-up, and death 
to be competing events. In a time-to-event analysis, we estimated the cause-speciﬁc cumulative incidence of ART 
outcomes (no-follow-up, loss to follow- up, transferred-out, stopped ART, died, or alive on ART) to compare the 
proportions of patients who had died, stopped ART, were lost to follow-up, or who were retained at 6, 12, 24 and 36 
months in patient-level and facility-level data. We plotted cause-speciﬁc cumulative incidence curves for all ART 
outcomes and stratiﬁed the analysis by indication for ART to examine the exact timing of loss to follow-up.18 We used 
logistic regressions with a random eﬀect for the facilities to examine predictors of no follow-up (yes or no) and loss to 
follow- up during the ﬁrst year on ART (yes or no), generating odds ratios (OR) and 95% CIs. In time-to-event analysis, 
we used competing-risk regression to examine factors associated with loss to follow-up during years 2 and 3 on ART, 
generating hazard ratios (HR) and 95% CIs.19 We adjusted analyses for age (15–19, 20–24, 25–29, and ≥30 years), type 
of facility (health centre, district hospital, faith-based hospital, or central hospital), and reason for starting ART 
(pregnancy, breastfeeding, or ART for own health). For patients whose cumulative medication a dherence at 6 months 
was more than 95%, 85–95%, and less than 85%, we plotted cause-speciﬁc cumulative incidence curves for loss to 
follow-up between months 7 and 36 on ART to compare the risk of loss to follow-up between patients with good and 
poor adherence. In a multivariable competing-risk regression, we calculated subdistribution HRs for risk of loss to 
follow-up for patients whose 6 month cumulative medication adherence was more than 95%, 85–95%, and less than 
85%. We adjusted for indication for ART, age, and facility. We plotted Kaplan-Meier curves for retention in care for 
pregnant and breastfeeding patients who started ART in the years 2011, 2012, and 2013, to examine time trends in 
retention. We used Stata version 13 for all statistical analyses. 
Role of the funding source 
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The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all data in the study and had ﬁnal responsibility for the decision to submit for 
publication.  
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Results 
We analysed facility-level data to calculate representative estimates for loss to follow-up and Option B+ programme 
retention. We included data for 29 768 women from 546 facilities (all facilities with available data), of whom 6648 
(22·3%) started ART at the 20 large health facilities included in the patient-level analysis. Patients who transferred to 
another facility were excluded (Table 1, Figure S1, appendix). At 12 months after the start of ART, of 26 658 patients, 
5746 (21·6%) were lost to follow-up and 20 475 (76·8%) were retained in care. At 24 months, of 25 849 patients, 7053 
(27·3 %) were lost to follow-up and 18 306 (70·8%) were retained. At 36 months, of 25 535 patients, 7186 (28·1%) 
were lost to follow-up, and 17 787 (69·7%) were retained in care, 427 (1·7%) had died, and 135 (0·5%) had stopped 
ART (Table 1). In a sensitivity analysis, we included all available data from 584 facilities, including those excluded from 
the main analysis because of missing data, and our results were similar (Appendix 
 
Table S11, appendix). 
We analysed patient-level data from 20 large health facilities to examine timing of loss to follow-up, predictors of no 
follow-up and loss to follow-up, and temporal trends in retention. In total, 29 145 patients were eligible for analysis 
(Fehler! Verweisquelle konnte nicht gefunden werden.). Patients were followed up for a total of 48 445 person-years, 
for a median duration of 1·8 years (IQR 0·5–2·8). Overall, 14 630 started ART for Option B+ and 14 515 women started 
ART for their own health. 11 151 women starting for Option B+ (76·2%) started ART while pregnant. At the start of 
ART, patients in Option B+ were younger than were those who started ART for their own health. 14 200 women in 
Option B+ (97·1%) and 3705 starting ART for their own health (25·5%) were initiated on tenofovir, lamivudine, and 
efavirenz. 10 743 (74·0%) women who started ART for their own health were initiated on a ﬁrst-line regimen of 
stavudine, lamivudine, and nevirapine (Table 2). 
In the 20 large facilities with patient-level data, retention in care was about 10% less than the national average. 
Retention in the Option B+ programme at 12 months after ART initiation, was 68·5% (95% CI 67·7–69·2), at 24 months 
it was 61·1% (60·3–61·9%), and at 36 months it was 56·3% (55·4–57·2;   
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Table  S2, appendix). Most patients who defaulted from care had no follow-up or were lost to follow-up in the ﬁrst 12 
months (Figure 1). 
We compared the risk of no-follow-up or loss to follow-up during years 1, 2, and 3 between groups of patients. 
Women in Option B+ who started ART while breastfeeding had more than twice the risk of no follow-up (adjusted OR 
[AOR] 2·47, 95% CI 2·14–2·85) compared with patients who started ART for their own health. Patients who started 
ART during pregnancy were almost ﬁve times more likely to have no follow-up visit (4·73, 4·27–5·24) than were 
patients who started for their own health (Table 3). 
Among patients who attended their ﬁrst follow-up visit, risk of loss to follow-up in the ﬁrst year of ART was slightly 
higher in pregnant women (AOR 1·61, 95% CI 1·48–1·76) than in women who started for their own health. 
Breastfeeding women had the same risk of loss to follow- up in the ﬁrst year of ART as did patients who started for 
their own health (1·05, 0·92–1·20). The pattern in year 2 was similar. In year 3, patients in all groups had a similar risk 
of loss to follow-up (p=0·2). Patients aged 24 years or younger were about twice as likely to default from care at any 
time during follow-up compared with patients aged 30 years or older at the start of ART (Table 3). Risk of loss to 
follow-up in years 1, 2, and 3 was reduced in faith-based hospitals compared with other types of facilities. 
Patients with poor adherence (cumulative medication adherence <85%) had the highest risk of loss to follow-up. Risk 
decreased in a linear fashion as adherence improved (Figure S2). Adjusted subdistribution HRs were 1·35 (95% CI 
1·21–1·52) for patients with cumulative medication adherence of 85–95% and 1·94 (1·78–2·13) for patients with 
cumulative medication adherence of less than 85% (p<0·0001) compared with patients with a 6 month cumulative 
medication adherence of more than 95%. 
Retention rates were similar between pregnant women who started ART in 2011, 2012, and 2013. Retention in care 
decreased with time in women who started ART while breastfeeding (Figure 2). 
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Discussion 
69·7% of all Malawian women who started ART under Option B+ were in care 3 years later. Loss to follow-up was high 
(21·6%) during the ﬁrst year of ART, moderate (5·7%) in year 2, and, low (0·8%) in year 3. Analysis of patient-level data 
from large facilities showed that most patients who defaulted from care failed to return to the clinic and had no 
follow-up. Women in Option B+ were at much higher risk of having no follow-up than were women who were not 
pregnant and began ART for their own health. The risk of loss to follow-up was higher for women in Option B+ than for 
those who started ART for their own health in years 1 and 2, but was not higher in year 3. Younger age was associated 
with an increased risk of defaulting from care at any point during follow-up. Women who had poor adherence to 
treatment during early ART were twice as likely to be lost to follow-up compared with patients who had optimum 
adherence. Risk of loss to follow-up in years 1, 2, and 3 was reduced in faith-based hospitals, which generally have 
better resources than do other types of health-care facilities. Retention rates were similar over time and did not 
improve as the programme matured. 
This study is likely to underestimate programme retention. We relied on data routinely collected during standard care, 
and health-care workers do not usually actively trace patients lost to follow-up. Patients who self- transferred to 
another facility without telling their former health-care providers are likely to be misclassiﬁed as lost to follow-up in 
routine data. A systematic review
20
 noted that almost one in ﬁve patients classiﬁed as being lost to follow-up in 
routine ART programmes had self-transferred to another facility, and were retained in care. A tracing study21 from 
Malawi showed that one in three women in Option B+ classiﬁed as being lost to follow-up from a large, urban district 
hospital had self-transferred or used ART from other sources. Only 54% of women no longer took their antiretroviral 
drugs.21 A cohort study from the Karonga district in Malawi accounted for self- transfer and followed up patients 
across all clinics in the district, reporting that 85% of patients in Option B+ were retained in care after 6 months, 22  
even though routine health facility records noted their retention as 78%. Analyses of routine data without active 
defaulter tracing tend to underestimate programme retention. Patient- level data might be especially prone to bias 
from unaccounted self-transfer because patient-level data were mainly collected in district and central hospitals and 
patients who initiate ART at these hospitals are more likely to self-transfer to lower level facilities that are closer to 
home than are patients who start ART at primary care facilities. 20,22 
Our results support reports of high attrition rates during early ART from previous studies of Option B+ from Malawi.5,14 
Many women might be reluctant to initiate ART, and high proportions of women with no follow-up might represent 
women who have not started ART despite being given the ﬁrst monthly dose. Often cited barriers to successful PMTCT 
uptake and retention include distance to clinics, having no money for transport, other diﬃculties in travelling, illness 
or weakness, side-eﬀects of ART, negative attitudes of health facility staﬀ, insuﬃcient treatment support, depression, 
denial of HIV infection, absence of male involvement, initiation of ART on the day of HIV diagnosis, the model of care 
implemented at the health facility, and fear that partners and community members will react badly, including fear of 
domestic violence. 12,21,23 Health-care workers should pay special attention to patients with early adherence problems 
because they are more likely to default from care. These patients might beneﬁt from targeted adherence 
interventions. 
In pregnant women, retention rates were similar over time and did not change as the programme matured, but 
breastfeeding women who started ART in 2013 had worse retention than did breastfeeding women who started ART 
in earlier calendar years. Deterioration of retention in breastfeeding mothers might result from the selection of a non-
representative sample of non-compliant or marginalised breastfeeding mothers who started ART during later calendar 
years. Breastfeeding mothers who started ART after the Option B+ roll-out in late 2012 and 2013 were those who 
either were not diagnosed during pregnancy or were reluctant to initiate treatment during pregnancy. By  contrast, 
breastfeeding mothers who started ART in 2011 and early 2012 are a representative sample of all childbearing women 
who happened to be breastfeeding during the B+ roll-out (ie, Option B+ was not yet available to them during 
pregnancy). 
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We assessed ART outcomes for up to 3 years after the start of ART and our study is the ﬁrst to use patient-level data 
to assess retention in care among women initiating ART for Option B+ who have passed the formal MTCT risk period. 
Although we have no data about the timing of weaning, few women in Malawi are likely to be breastfeeding after 2 
years; the median duration of breastfeeding is 23 months.24 Our data suggest that if women are retained in care 
throughout breastfeeding, they are likely to continue treatment afterwards. In Malawi, Option B+ is deliberately 
presented as providing lifelong treatment to prevent MTCT and improve maternal health. Qualitative data show that 
patients in Option B+ understand the maternal health beneﬁts of ART and are motivated to continue with it beyond 
the MTCT risk period. 12 However, we could not assess the number of women lost to the programme along the full 
PMTCT cascade because electronic data are only collected for patients who start ART. Many women are not tested for 
HIV during pregnancy
25
 or are lost between HIV testing and counselling and ART uptake.
4,26
 Clinical and immunological 
stage at ART initiation was often missing. CD4 cell counts are rarely measured for pregnant and breastfeeding women 
in Malawi, and although WHO clinical staging is mandatory for all HIV patients,
2
 WHO stage-deﬁning conditions at ART 
initiation are often not reported. 
Our data show that the Option B+ programme, in which all HIV-positive pregnant and breastfeeding women are 
initiated on lifelong ART, is feasible and acceptable. Women retained in care after breastfeeding were generally 
motivated to continue ART. This adds weight to the argument that Option B+ is superior to prescription of ART for 
women with high CD4 cell counts only during pregnancy and breastfeeding (Option B). If HIV-positive women stop ART 
after breastfeeding, their CD4 cell counts rapidly decline
9
 and the maternal health beneﬁts of early ART
10
 diminish. 
Because fertility rates are high and breastfeeding is prolonged in Malawi and other sub- Saharan African countries, a 
start-and-stop approach to treatment might not save money, especially in view of the fact that many women will need 
ART for their own health soon after they discontinue ART for PMTCT.
9
 
Randomised controlled trials have provided evidence for the beneﬁt of immediate initiation of ART for all HIV-infected 
individuals. 
10,27
 Evidence from these studies retrospectively supports the aims of the Malawi Ministry of Health when 
it introduced Option B+ in 2011. Retention in the ﬁrst year remains the big challenge facing the Option B+ programme, 
but loss to follow-up during year 2 is moderate and risk of loss to follow-up is low during year 3, when women stop 
breastfeeding. 
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Tables & Figures  
Table 1 Treatment outcomes of patients in Option B+ by time since start of ART 
  
Number of 
patients 
 
Number (%) 
of patients 
transferred1 
 
Number of patients 
not transferred2 
 
Percentage of patients not transferred 
(confidence interval)   
Lost to follow-
up3 
 Stopped 
ART4 
 Dead
5 
 
 Retained in 
care6 
    6 months  29,768 
 
1,685 (5.7) 
 
28,083 
 17.0 
(16.5-17.4)  
0.2 
(0.2-0.3)  
0.7 
(0.6-0.8)  
82.1 
(81.7-82.6) 
   12 months  29,007 
 
2,349 (8.1) 
 
26,658 
 21.6 
(21.1-22.1)  
0.5 
(0.5-0.6)  
1.1 
(1.0-1.2)  
76.8 
(76.3-77.3) 
   24 months  29,121 
 
3,272 (11.2) 
 
25,849 
 27.3 
(26.7-27.8)  
0.6 
(0.5-0.7)  
1.3 
(1.2-1.5)  
70.8 
(70.3-71.4) 
   36 months  29,313 
 
3,778 (12.9) 
 
25,535 
 28.1 
(27.6-28.7)  
0.5 
(0.4-0.6)  
1.7 
(1.5-1.8)  
69.7 
(69.1-70.2) 
Data are n (%) or % (95% CI) unless indicated otherwise. Results from analysis of aggregated facility-level data for patients starting 
ART between October, 2011, and June, 2012, from 546 health facilities in Malawi. We included cohorts with available outcome data 
at 6, 12, 24, and 36 months.  ART=antiretroviral therapy.  1Transferred to another facility before the end of the reporting period (6, 
12, 24, or 36 months after start of ART). 2Started ART and not transferred to another facility before the end of reporting period. 
3More than 60 days late for a follow-up visit and did not return to care thereafter. 4Stopped taking ART. 5Known to be dead. 
6Retained alive on ART and under active follow-up. 
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Table 2 Patients’ characteristics at start of ART 
   Reason for ART initiation  Total 
 
 Option B+ because of 
pregnancy   
Option B+ because of 
breastfeeding   For own health 
  
Number of patients (%)  11151 (38·3%)  3479 (11·9%)  14515 (49·8%)  29145 (100·0%) 
Age (in years)             
   15-19 (%)  828 (7·4%)  188 (5·4%)  329 (2·3%)  1345 (4·6%) 
   20-24 (%)  2697 (24·2%)  750 (21·6%)  1200 (8·3%)  4647 (15·9%) 
   25-29 (%)  4330 (38·8%)  1374 (39·5%)  3270 (22·5%)  8974 (30·8%) 
   30+ (%)  3296 (29·6%)  1167 (33·5%)  9716 (66·9%)  14179 (48·6%) 
   Median (IQR)  27 (23-31)  28 (24-32)  34 (29-42)  30 (25-36) 
Year of ART initiation (%)             
   2011  1541 (13·8%)  1165 (33·5%)  2768 (19·1%)  5474 (18·8%) 
   2012  5083 (45·6%)  1434 (41·2%)  6459 (44·5%)  12976 (44·5%) 
   2013  4527 (40·6%)  880 (25·3%)  5288 (36·4%)  10695 (36·7%) 
WHO clinical stage (%)             
   Stage 1  10937 (98·1%)  3301 (94·9%)  5623 (38·7%)  19861 (68·1%) 
   Stage 2  106 (1·0%)  178 (5·1%)  1541 (10·6%)  1825 (6·3%) 
   Stage 3  88 (0·8%)  0 (0·0%)  6337 (43·7%)  6425 (22·0%) 
   Stage 4  20 (0·2%)  0 (0·0%)  1014 (7·0%)  1034 (3·5%) 
First-line ART             
   TDF 3TC EFV   10943 (98·1%)  3257 (93·6%)  3705 (25·5%)  17905 (61·4%) 
   d4T 3TC NVP  182 (1·6%)  217 (6·2%)  10743 (74·0%)  11142 (38·2%) 
   Other  26 (0·2%)  5 (0·1%)  67 (0·5%)  98 (0·3%) 
Data are n (%) unless indicated otherwise and are from women who attended 20 large health facilities with patient-level data. 
ART=antiretroviral therapy. 
  
 Table 3 Predictors of no follow-up and loss to follow-up 
 Univariable analysis  Multivariable analysis 
  No-follow-up 
after ART start
1
 
 LTF during year 1 on 
ART 
 LTF during year 2 
on ART 
 LTF during year 3 
on ART 
 No-follow-up after 
ART start 
 LTF during year 1 
on ART 
 LTF during year 2 
on ART 
 LTF during year 3 
on ART 
  OR  
(95% CI) 
[p-value] 
T OR 
(95% CI) 
[p-value] 
T  SHR 
(95% CI) 
[p-value] 
T SHR 
(95% CI) 
[p-value] 
T aOR 
(95% CI) 
[p-value] 
T aOR  
(95% CI) 
[p-value] 
T aSHR 
(95% CI) 
[p-value] 
T aSHR 
(95% CI) 
[p-value] 
ART eligibility                
    Own health  1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[0.1809] 
    B+ pregnant 5.65 
(5.13-6.23) 
 2.00 
(1.84-2.16) 
 1.81 
(1.61-2.03) 
 1.53 
(1.28-1.82) 
 4.73 
(4.27-5.24) 
 1.61 
(1.48-1.76) 
 1.35 
(1.19-1.53) 
 1.15 
(0.95-1.40) 
    B+ breastfeeding 2.89 
(2.52-3.31) 
 1.19 
(1.05-1.35) 
 1.49 
(1.27-1.76) 
 1.17 
(0.92-1.48) 
 2.47 
(2.14-2.85) 
 1.05 
(0.92-1.20) 
 1.18 
(1.00-1.40) 
 0.94 
(0.73-1.21) 
Age (years)                
   ≥30 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
   25-29 2.01 
(1.83-2.21) 
 1.55 
(1.42-1.69) 
 1.67 
(1.47-1.90) 
 1.60 
(1.32-1.93) 
 1.32 
(1.19-1.45) 
 1.33 
(1.21-1.46) 
 1.51 
(1.32-1.73) 
 1.54 
(1.26-1.88) 
   20-24 2.83 
(2.56-3.14) 
 2.23 
(2.02-2.47) 
 2.73 
(2.37-3.14) 
 2.37 
(1.90-2.94) 
 1.64 
(1.47-1.83) 
 1.83 
(1.64-2.03) 
 2.37 
(2.03-2.75) 
 2.23 
(1.76-2.81) 
   15-19 3.41 
(2.93-3.97) 
 2.79 
(2.39-3.26) 
 2.87 
(2.30-3.57) 
 3.06 
(2.21-4.24) 
 1.92 
(1.64-2.25) 
 2.21 
(1.88-2.60) 
 2.43 
(1.94-3.05) 
 2.82 
(2.02-3.94) 
Facility type                
   Health Centre 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[<0.0001] 
 1.00 
[0.0007] 
 1.00 
[0.0743] 
 1.00 
[0.0001] 
 1.00 
[<0.0001] 
 1.00 
[0.0113] 
   District Hospital 1.15 
(1.01-1.30) 
 0.83 
(0.74-0.93) 
 0.79 
(0.68-0.93) 
 0.77 
(0.61-0.97) 
 1.21 
(0.81-1.81) 
 0.79 
(0.54-1.15) 
 0.84 
(0.72-0.98) 
 0.81 
(0.64-1.03) 
   Mission Hospital 0.49 
(0.40-0.61) 
 0.35 
(0.29-0.44) 
 0.40 
(0.31-0.53) 
 0.45 
(0.30-0.66) 
 0.75 
(0.45-1.25) 
 0.42 
(0.26-0.69) 
 0.49 
(0.37-0.64) 
 0.52 
(0.35-0.76) 
   Central Hospital 0.71 
(0.60-0.84) 
 1.01 
(0.87-1.17) 
 0.67 
(0.54-0.83) 
 0.70 
(0.51-0.96) 
 0.96 
(0.57-1.64) 
 1.19 
(0.72-1.96) 
 0.81 
(0.65-1.02) 
 0.79 
(0.57-1.10) 
Patient-level data from 20 large facilities. Multivariable analyses are adjusted for all variables shown in the table. We defined patients as having no follow-up if they were >60 days late for a follow-up 
visit and did not return to care thereafter. We defined patients as lost to follow-up (LTF) if they attended at least one follow-up visit and were more than 60 days late for a subsequent visit (during 
time period) and did not return to care thereafter. p-value shows whether a variables is a significant predictor of outcome overall. OR=odds ratio. aOR=adjusted odds ratio. HR=subdistribution hazard 
ratio. aHR=adjusted subdistribution hazard ratio, CI=confidence interval. 
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Figure 1 Cumulative incidence of ART outcomes for patients at 20 large 
Treatment outcomes are compared between three groups on the basis of indication for ART. Option B+ indication and ART started during 
pregnancy (top panel), Option B+ indication and ART started while breastfeeding (middle panel), and WHO stage 3 or 4 disease or CD4 cell 
count meeting the ART eligibility threshold (bottom panel). Estimates derived from competing-risk regression. ART=antiretroviral therapy. 
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Figure 2 Retention in care by indication for Option B+ and year of ART initiation 
Data are for women who attended 20 large facilities with patient-level data. Kaplan-Meier curves show retention in care for pregnant or 
breastfeeding women in Option B+ who started ART in 2011, 2012, or 2013. In this analysis of temporal trends in retention, patients were 
classified as lost to follow-up if they were more than 150 days late for an appointment, even if they returned to care thereafter. 
ART=antiretroviral therapy. 
Numbers at risk:
            -Breastfeeding 2011 787 665 569
            -Breastfeeding 2012 899 743 81
            -Breastfeeding 2013 505 43 0
    -Pregnant 2011 812 703 588
    -Pregnant 2012 2653 2122 157
    -Pregnant 2013 2360 128 0
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Appendix 
 
Table S1 Sensitivity analysis of treatment outcomes of patients in Option B+ by time since start of ART  
  
Number of 
patients 
 
Number (%) 
of patients 
transferred1 
 
Number of patients 
not transferred2 
 
Percentage of patients not transferred 
(confidence interval)   
Lost to follow-
up3 
 Stopped 
ART4 
 Dead
5 
 
 Retained in 
care6 
    6 months  29,768 
 
32,041 
 
1,837 (5.7) 
 
30,204 
 17.0  
(16.6-17.4)  
0.2  
(0.2-0.3)  
0.7  
(0.6-0.8) 
   12 months  29,007 
 
31,579 
 
2,591 (8.2) 
 
28,988 
 21.6  
(21.2-22.1)  
0.5  
(0.4-0.6)  
1.1  
(0.9-1.2) 
   24 months  29,121 
 
32,526 
 
3,597 (11.1) 
 
28,929 
 27.6  
(27.1-28.1)  
0.6  
(0.5-0.7)  
1.3  
(1.2-1.4) 
   36 months  29,313 
 
34,675 
 
4,537 (13.1) 
 
30,138 
 27.7  
(27.2-28.2)  
0.6  
(0.5-0.6)  
1.9  
(1.8-2.1) 
Data are n (%) or % (95% CI) unless indicated otherwise. Results from analysis of aggregated facility-level data for patients 
starting ART between October, 2011, and June, 2012, from 584 health facilities in Malawi. ART=antiretroviral therapy.  
1Transferred to another facility before the end of the reporting period (6, 12, 24, or 36 months after start of ART). 2Started 
ART and not transferred to another facility before the end of reporting period. 3More than 60 days late for a follow-up visit 
and did not return to care thereafter. 4Stopped taking ART. 5Known to be dead. 6Retained alive on ART and under active 
follow-up. 
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Table S2 Treatment outcomes of women starting ART 
 
 Number 
of 
facilities 
 Number of 
patients 
 No-follow-up
 
% (CI)  
 
LTF 
(60 days) 
% (CI) 
 Stopped ART
 
% (CI) 
 Dead
 
% (CI) 
 
RIC 
 % (CI) 
6-month outcomes                
   B+ pregnant  20 
 
7,541  
18.7             
(18.0-19.5)  
9.4             
(8.9-10.0)  
0.1             
(0.1-0.2)  
0.2             
(0.1-0.3)  
71.5             
(70.7-72.4) 
   B+ breastfeeding  20 
 
2,643  
10.7             
(9.7-11.8)  
6.2             
(5.5-7.1)  
0.0             
(0.0-0.2)  
0.5             
(0.3-0.8)  
82.5             
(81.2-83.7) 
   B+ total  20 
 
10,184  
16.8             
(16.2-17.5)  
8.7             
(8.2-9.2)  
0.1             
(0.0-0.1)  
0.3             
(0.2-0.4)  
74.1             
(73.4-74.8) 
   ART for own health       20 
 
11,533  
3.9             
(3.6-4.3)  
6.6             
(6.2-7.0)  
0.1             
(0.0-0.1)  
3.3             
(3.0-3.6)  
86.1             
(85.5-86.7) 
12-month outcomes               
   B+ pregnant  20 
 
6,598  
18.7             
(18.0-19.5)  
14.8             
(14.1-15.4)  
0.6             
(0.4-0.7)  
0.3             
(0.2-0.5)  
65.6             
(64.7-66.5) 
   B+ breastfeeding  20 
 
2,392  
10.7             
(9.7-11.8)  
10.5             
(9.5-11.6)  
0.0             
(0.0-0.2)  
0.7             
(0.5-1.1)  
78.0             
(76.5-79.3) 
   B+ total  20 
 
8,990  
16.9             
(16.3-17.5)  
13.8             
(13.2-14.4)  
0.5             
(0.3-0.6)  
0.4             
(0.3-0.5)  
68.5             
(67.7-69.2) 
   ART for own health  20 
 
10,599  
4.0             
(3.6-4.3)  
9.7             
(9.2-10.2)  
0.1             
(0.1-0.2)  
4.1             
(3.8-4.5)  
82.1             
(81.4-82.7) 
24-month outcomes               
   B+ pregnant  20 
 
4,023  
18.7             
(18.0-19.5)  
21.6             
(20.8-22.5)  
1.0             
(0.9-1.3)  
0.4             
(0.3-0.6)  
58.1             
(57.2-59.1) 
   B+ breastfeeding  20 
 
1,782  
10.7             
(9.7-11.8)  
17.3             
(16.0-18.6)  
0.3             
(0.1-0.5)  
1.0             
(0.7-1.4)  
70.7             
(69.1-72.3) 
   B+ total  20 
 
5,805  
16.9             
(16.3-17.5)  
20.6             
(19.9-21.3)  
0.9             
(0.7-1.0)  
0.6             
(0.5-0.7)  
61.1             
(60.3-61.9) 
   ART for own health  20 
 
7,143  
4.0             
(3.6-4.3)  
14.5             
(13.9-15.1)  
0.2             
(0.1-0.3)  
4.6             
(4.3-5.0)  
76.7             
(76.0-77.4) 
36-month outcomes               
   B+ pregnant  20 
 
1,452  
18.7             
(18.0-19.5)  
26.3             
(25.3-27.3)  
1.2             
(1.0-1.4)  
0.6             
(0.5-0.8)  
53.2             
(52.1-54.2) 
   B+ breastfeeding  20 
 
1,003  
10.7             
(9.7-11.8)  
21.6             
(20.1-23.2)  
0.5             
(0.3-0.8)  
1.0             
(0.7-1.5)  
66.1             
(64.4-67.9) 
   B+ total  20 
 
2,455  
16.9             
(16.3-17.5)  
25.1             
(24.3-25.9)  
1.0             
(0.9-1.2)  
0.7             
(0.6-0.9)  
56.3             
(55.4-57.2) 
   ART for own health  20 
 
2,967  
4.0             
(3.6-4.3)  
18.5             
(17.8-19.3)  
0.2             
(0.2-0.3)  
5.1             
(4.7-5.5)  
72.1             
(71.3-73.0) 
Patient-level data from 20 large facilities. Data are cumulative incidence of ART outcome (in percent) at 6, 12, 24 and 36 
months after start of ART. We defined patients as having no follow-up if they were >60 days late for a follow-up visit and 
did not return to care thereafter. We defined patients as lost to follow-up (LTF) if they attended at least one follow-up visit 
and were more than 60 days late for a subsequent visit (during time period) and did not return to care thereafter. 
RIC=Retained alive on ART and under active follow-up, CI=confidence interval 
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Figure S3 Inclusion of patients 
Retention in care during the first 3 years of ART for women in Malawi's Option B+ programme 
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Figure S2 Cumulative incidence of loss to follow-up by cumulative medication adherence and indication for ART 
Data are for women who attended 20 large facilities with patient-level data. Cumulative proportion of lost to follow-up between month 7 
and 36 on ART among patients with a six-month cumulative medication adherence (CMA) of > 95%, 95-85% or <85%. Six-month CMA was 
defined as the percentage of days a patient had drug available during the first six months on ART. The analysis is stratified by indication for 
ART (Option B+ indication during pregnancy (top panel), while breastfeeding (middle panel) or ART for own health (bottom panel). 
 
 
Numbers at risk:
 - Adherence <85% 2680 1559 551
   - Adherence 85-95% 944 592 225
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Numbers at risk:
 - Adherence <85% 598 406 259
   - Adherence 85-95% 365 283 158
- Adherence >95% 1416 1092 586
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   - Adherence 85-95% 944 592 225
- Adherence >95% 2908 1854 674
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
0 6 12 18 24 30 36
Time from ART initiation (months)
ART for own health
